The cardiovascular effects of metformin: Lost in translation?

Current Opinion in Lipidology

Volumn 25, Issue 6, 2014, Pages 446-451

  Riksen, Niels P ^a   Tack, Cornelis J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Infarct size; Metformin; Remodeling; Translation

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; DIABETES MELLITUS; DRUG EFFICACY; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; HEART ATRIUM REMODELING; MOUSE; MYOCARDIAL INFARCTION; PATHOLOGY; TREATMENT FAILURE;

RODENTIA;

ANIMALS; ATHEROSCLEROSIS; ATRIAL REMODELING; CAROTID INTIMA-MEDIA THICKNESS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; MYOCARDIAL INFARCTION; TREATMENT FAILURE;

EID: 84927698204     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000128     Document Type: Review

References (41)

1. Nauta ST, Deckers JW, van Domburg RT, Akkerhuis KM. Sex-related trends in mortality in hospitalized men and women after myocardial infarction between 1985 and 2008: equal benefit for women and men. Circulation 2012; 126:2184-2189.
2. VelagaletiRS, Pencina MJ, Murabito JM, et al. Long-termtrends in the incidence of heart failure after myocardial infarction. Circulation 2008; 118:2057-2062.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
4. El Messaoudi SE, Rongen GA, de Boer RA, Riksen NP. The cardioprotective effects of metformin. Curr Opin Lipidol 2011; 22:445-453.
5. El Messaoudi S, Schreuder TH, Kengen RD, et al. Impact of metformin on endothelial ischemia-reperfusion injury in humans in vivo: a prospective randomized open, blinded-endpoint study. PLoS One 2014; 9:e96062.
6. Lexis CP, van der Horst IC, Lipsic E, et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 2014; 311:1526-1535.
7. Preiss D, Lloyd SM, Ford I, et al. Metformin for nondiabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diab Endocrinol 2014; 2:116-124.
8. & Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013; 36:1304-1311.
9. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diab Obes Metab 2011; 13:221-228.
10. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012; 9:e1001204.
11. Marquie G. Metformin action on lipid metabolism in lesions of experimental aortic atherosclerosis of rabbits. Atherosclerosis 1983; 47:7-17.
12. El Messaoudi S, Rongen GA, Riksen NP. Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep 2013; 15:314.
13. Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004; 256:1-14.
14. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137:25-33.
15. Bekkering S, Joosten LA, van der Meer JW, et al. Trained innate immunity and atherosclerosis. Curr Opin Lipidol 2013; 24:487-492.
16. Tsoyi K, Jang HJ, Nizamutdinova IT, et al. Metformin inhibitsHMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 2011; 162:1498-1508.
17. Christiansen CF, Johansen MB, Christensen S, et al. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. Crit Care 2013; 17:R192.
18. Wan X, Huo Y, Johns M, et al. 5'-AMP-activated protein kinase-activating transcription factor 1 cascade modulates human monocyte-derived macrophages to atheroprotective functions in response to heme or metformin. Arterioscler Thromb Vasc Biol 2013; 33:2470-2480.
19. Lu J, Ji J, Meng H, et al. The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. Cardiovasc Diabetol 2013; 12:58.
20. Meaney E, Vela A, Samaniego V, et al. Metformin, arterial function, intimamedia thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol 2008; 35:895-903.
21. Frohlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013; 34:1714-1722.
22. Riksen NP, Smits P, Rongen GA. Ischaemic preconditioning: from molecular characterization to clinical application. Part II. Neth J Med 2004; 62:409-423.
23. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359:473-481.
24. Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012; 5:288-295.
25. Whittington HJ, Hall AR, McLaughlin CP, et al. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 2013; 27:5-16.
26. Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008; 57:696-705.
27. Paiva M, Riksen NP, Davidson SM, et al. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009; 53:373-378.
28. Bhamra GS, Hausenloy DJ, Davidson SM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008; 103:274-284.
29. Yin M, van der Horst IC, van Melle JP, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol 2011; 301:H459-H468.
30. Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009; 104:403-411.
31. Lexis CP, Wieringa WG, Hiemstra B, et al. Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. Cardiovasc Drugs Ther 2014; 28:163-171.
32. van den Munckhof I, Riksen N, Seeger JP, et al. Aging attenuates the protective effect of ischemic preconditioning against endothelial ischemiareperfusion injury in humans. Am J Physiol Heart Circ Physiol 2013; 304: H1727-1732.
33. Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, et al. Remote Ischemic Preconditioning Provides Early and Late Protection Against Endothelial Ischemia-Reperfusion Injury in Humans: Role of the Autonomic Nervous System. J Am Coll Cardiol 2005; 46:450-456.
34. Li J, Xu JP, Zhao XZ, et al. Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention. Cardiology 2014; 127:133-139.
35. Habib A, Karmali V, Polavarapu R, et al. Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. J Am Coll Cardiol 2013; 61:971-980.
36. Habib A, Karmali V, Polavarapu R, et al. Metformin impairs endothelialization after placement of newer generation drug eluting stents. Atherosclerosis 2013; 229:385-387.
37. Liu X, Chhipa RR, Pooya S, et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A 2014; 111:E435-444.
38. Martinet W, De Loof H, De Meyer GR. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis 2014; 233:601-607.
39. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drugeluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115:2435-2441.
40. Hausenloy DJ, Baxter G, Bell R, et al. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 2010; 105:677-686.
41. van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? PLoS Med 2010; 7:e1000245.